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Abstract. We investigated the effects of α1- and β2-adrenergic agonists on 
hepatocyte growth factor (HGF)-stimulated mitogen-activated protein kinase 
(MAPK) isoforms in primary cultures of adult rat hepatocytes. Hepatocytes 
were isolated and cultured with HGF (5 ng/ml) and/or α- and β-adrenergic 
agonists. Phosphorylated MAPK isoforms (p42 and p44 MAPK) were detected 
by Western blotting analysis using anti-phospho-MAPK antibody. The results 
show that HGF increased phosphorylation of p42 MAPK by 2.2-fold within 3 
min. The HGF-induced MAPK activation was abolished by AG1478 
treatment (10-7 M). The MEK (MAPK kinase) inhibitor PD98059 (10-６ M) 
completely inhibited the HGF-dependent increase in MAPK activity. 
Phenylephrine (10-6 M) and metaproterenol (10-6 M) alone had no effect in the 
absence of HGF, but significantly increased p42 MAPK induction by HGF. 
Moreover, the cell-permeable cAMP analog, 8-bromo cAMP (10-7 M), and 
phorbol 12-myristate 13 acetate (10-7 M) potentiated HGF-induced MAPK 
phosphorylation. The effects of these analogs were antagonized by the protein 
kinase A (PKA) inhibitor H-89 (10-7 M), and the protein kinase C (PKC) 
inhibitor sphingosine (10-6 M), respectively. These results suggest that direct 
or indirect activation of both PKA and PKC represent a positive regulatory 
mechanism for stimulating MAPK induction by HGF.        
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cross-talk 
 
1. Introduction 
Hepatocyte growth factor (HGF) has multiple biological activities on a wide 
variety of cell types (1-4). HGF appears to trigger liver regeneration after 
partial hepatectomy and acute liver cell necrosis caused by chemicals in vivo 
(5-8). The response of adult rat hepatocytes to HGF has also been 
investigated extensively with respect to DNA synthesis and proliferation in 
vitro, and HGF is now known to be a potent hepatocyte mitogen (9). More 
recently, we reported that HGF is able to rapidly stimulate hepatocyte DNA 
synthesis and proliferation during short-term (e.g., 4 h) culture. In addition, 
the hepatocyte DNA synthesis and proliferation produced by HGF was 
inhibited depending on initial plating density. Furthermore, we found that 
hepatocyte DNA synthesis and proliferation were potentiated by both α1- and 
β2-adrenergic agonists (10). 
 The signal transduction pathways activated in response to HGF in 
hepatocytes and other cell types have become more clearly understood (3, 11- 
15). Using specific inhibitors of signal transducers, we pharmacologically 
demonstrated that receptor tyrosine kinase, phosphoinositide 3-kinase, 
phospholipase C and ribosomal p70 S6 kinase activities are essential for 
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HGF-induced DNA synthesis and proliferation in primary cultures of adult 
rat hepatocytes (10). 
 In addition, mitogen-activated protein kinase (MAPK) is now known to be 
activated in response to a large number of mitogenic stimuli, and the enzyme 
is a key participant in the response to various growth factors and cytokines 
(12, 16). In order to better understand the HGF-mediated signaling pathway, 
we investigated whether activation of MAPK isoforms, ERK1 and ERK2, is 
involved in HGF-induced DNA synthesis and proliferation in primary 
cultures of adult rat hepatocytes.  
Catecholamines (e.g., norepinephrine and its analogs) have been shown to 
be involved in regulation of liver function (e.g., lipid metabolism, 
carbohydrate metabolism and cell growth). There are several types of 
catecholamine receptors, β1- and β2-receptors, that stimulate adenylate 
cyclase, while α2-receptors inhibit its activity (17). α1-Receptors are related to 
phospholipase C activation and subsequent increases in inositolphosphate 
turnover and diacylglycerol production (10, 18). Although, some investigators 
have reported that the α1- and β-adrenergic responses are related to 
adrenergic regulation of carbohydrate metabolism in liver from normal adult 
rats and cultured hepatocytes (17, 19, 20). There are few studies regarding 
the adrenergic regulation of MAPK activity induced by growth factors in liver 
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cells. In the present study, therefore, we examined whether α1- and 
β2-adrenergic agonists can modulate HGF-induced MAPK isoform activities. 
The results obtained here indicate that HGF phosphorylates one of the 
MAPK isoforms, p42 MAPK, but not p44 MAPK, within 3 min. Moreover, 
both phenylephrine and metaproterenol potentiated p42 MAPK 
phosphorylation induction by HGF. The physiological significance of 
cross-talk between the HGF pathway and α1- and β2-adrenergic 
receptor-mediated pathway in regulating hepatocyte proliferation is also 
discussed. 
 
2. Materials and Methods 
2.1 Animals 
 Male Wistar rats (weight 200-220 g) were obtained from Saitama 
Experimental Animal Co. (Saitama, Japan). Rats were acclimated in the 
humidity- and temperature-controlled room for at least 3 days before 
experimentation, and were fed a standard diet and given tap water ad 
libitum. Rats were handled in accordance with the National Institutes of 
Health Guidelines for Care and Use of Laboratory Animals. 
2.2. Hepatocyte isolation and culture. 
 Male Wistar rats were anesthetized by intraperitoneal injection of sodium 
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pentobarbital (45 mg/Kg). Two-step in-situ collagenase perfusion was 
performed to facilitate disaggregation of adult rat livers, as described 
previously (21). After perfusion, cells were dispersed in Ca2+-free Hanks’ 
solution. Cells were then washed three times by slow centrifugation (120 g × 
1 min). Hepatocyte viability was monitored by Trypan blue dye exclusion. On 
average, more than 96% of the cells remained intact.  
 Isolated hepatocytes were plated onto collagen-coated plastic culture dishes 
(35 mm diameter) at a density of 3.3 × 104 cells/cm2 in Williams′ medium E 
containing 5% bovine calf serum, 0.1 nM dexamethasone for 3 h at 37°C in 
5% CO2 in air. The medium was then changed, and the cells were cultured in 
serum- and dexamethasone-free Williams′ medium E containing HGF (5 
ng/ml) with or without α1- and β2-adrenergic agonists and/or specific effectors 
or inhibitors of signal transducers for the indicated times at 37°C. 
2.3. Measurement of MAPK activity 
 Phosphorylated MAPK isoforms (P-p42 MAPK, ERK 2; and P-p44 MAPK, 
ERK 1) were identified by Western blotting analysis using 
anti-phospho-MAPK (ERK1, 2) monoclonal antibody as described by Towbin 
et al., (22). Phosphorylated MAPK activity is normalized to the total MAPK. 
Briefly, cultured hepatocytes were washed once with ice-cold 
phosphate-buffered saline (pH 7.4) and 0.2 ml of lysis buffer added, after 
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which the hepatocytes were harvested. After centrifugation at 16,300 × g for 
30 min at 4°C, cell lysates were denatured in boiling water for 5 min. 
Samples of the supernatant (30 μg of protein) were subjected to SDS-PAGE 
using a 10% acrylamide resolving gel according to the method of Laemmli 
(23). After electrophoresis, proteins were transferred to Immobilon-P 
membranes.  
 For detection of phosphorylated extracellular-regulated protein kinase p44 
MAPK (ERK 1) and p42 MAPK (ERK2), the membranes were immersed in 
Tris-buffered saline (pH 7.4) containing 1% bovine serum albumin. The 
membranes were then incubated with an antibody (1 μg/ml) against 
phospho-MAPK and/or MAPK, and were washed as described previously (22). 
Antibody binding was visualized by incubation with a horseradish 
peroxidase-conjugated donkey anti-rabbit IgG secondary antibody (1:3000 
dilution; 24) followed by enhanced chemiluminescence detection (ECL Kit, 
Amersham). Densitometry analysis was performed using NIH Image version 
1.68 for Macintosh. Data were calculated in arbitrary units and are expressed 
as means ± S.E.M. 
 Cytosolic protein in hepatocytes was quantified by modification of the Lowry 
procedure with bovine serum albumin as a standard (25). 
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2.4. Materials 
 The following reagents were obtained from Sigma Chemical Co. (St. Louis, 
MO, USA): dexamethasone, aprotinin, aphidicolin, HGF (human 
recombinant), AG1478 (N-[3-chlorophenyl]-6,7-dimethoxy-4-quinazolinamine), 
8-bromo-cAMP, wortmannin, H-89 (N-[2-(p-bromocinnamylamino) 
ethyl]-5-isoquinolinesulfonamide dihydrochloride), metaproterenol 
hemisulfate, sphingosine hydrochloride, phenylephrine hydrochloride. 
PD98059 (2’-amino-3’-methoxyflavone) was obtained from 
Calbiochem-Behring Corp. (La Jolla, CA, USA). Rapamycin and 
12-O-tetradecanoylphorbol-13-acetate (phorbol ester, TPA) were obtained 
from Research Biochemicals Inc. (Natick, MA, USA). Williams’ medium E 
and newborn calf serum were purchased from Flow Laboratories (Irvine, 
Scotland). Collagenase (type II) was obtained from Worthington Biochemical 
Co. (Freehold, NJ, USA).  Anti-phospho-p42/p44 MAPK monoclonal antibody 
and anti-p42/p44 MAPK monoclonal antibody were obtained from Cell 
Signaling TECHNOLOGY (Danvers, MA, USA). All other reagents were of 
analytical grade.  
2.5. Statistical analysis 
 Group comparisons were made by ANOVA for unpaired data followed by 
post hoc analysis using Dunnett’s multiple comparison test. Differences 
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P<0.05 were considered to be statistically significant. 
 
3. Results 
3.1. Time course and patterns of MAPK isoform activity stimulated by HGF 
 It has been reported that MAPK plays an important role in the proliferation 
of hepatocytes and other cells induced by growth factors and cytokines (26-29). 
Figure 1A shows the typical detectable pattern of phospho-MAPK on Western 
blotting analysis. The phosphorylated p42 MAPK band was induced after 
only 1 min and peaked (about 2-fold increase) between 3 and 5 min after 
addition of 5 ng/ml HGF, a concentration that stimulated hepatocyte 
proliferation (Fig. 1B) (10). p44 MAPK was not significantly affected by either 
medium alone (control) or HGF treatment (Fig. 1C). 
3.2. Effects of specific inhibitors of signal transducers on HGF-stimulated 
MAPK isoform activity 
 In order to characterize the involvement of MAPK in the mitogenic pathway 
induced by HGF, we investigated the effects of the receptor tyrosine kinase 
inhibitor AG1478 (10-7 M; 30), the PI3 kinase inhibitor wortmannin (10-7 M; 
31, 32), the MEK inhibitor PD98059 (10-6 M; 27) and the p70S6 kinase 
inhibitor rapamycin (10 ng/ml; 33) on HGF-induced MAPK activity. As shown 
in Fig. 2, the phosphorylation of ERK2 induced by HGF (5 ng/ml) at 5 min 
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was almost completely blocked by AG1478, wortmannin and PD98059. 
However, rapamycin did not affect the HGF-induced MAPK activity. 
Phosphorylation of p44 MAPK in the presence of 5 ng/ml HGF was not 
affected by these inhibitors.  
3.3. Activation of p42 MAPK produced by HGF is potentiated by 
β2-adrerenergic agonist metaproterenol 
 The time course of effects of β2-adrerenergic agonists on MAPK activity 
induction by 5 ng/ml HGF was investigated using the β2-adrerenergic agonist 
metaproterenol. When hepatocytes were stimulated with HGF in the 
presence of the β2-adrerenergic agonist metaproterenol (10-6 M), the agent 
caused a more rapid and significant increase in p42 MAPK activity than HGF 
alone, reaching a peak at 5 min after addition (about 3-fold increase from 
baseline) and rapidly declining to basal levels within 30 min (Fig. 3A and 3B). 
In contrast, metaproterenol alone did not significantly stimulate p42 MAPK 
activity (data not shown). Metaproterenol in the presence of HGF did not 
significantly stimulate p44 MAPK phosphorylation (Fig. 3C). Therefore, it 
was found that metaproterenol (10-6 M) potentiated the HGF-induced p42 
MAPK activity.  
3.4. Effect of specific inhibitors of signal transducers on metaproterenol 
and/or 8-bromo cAMP-induced MAPK isoform activity in the presence of HGF 
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 In order to investigate the potentiating mechanisms for the β2-adrenergic 
receptor/protein kinase A (PKA) pathway in induction of p42 MAPK activity 
by HGF, we examined the effects of metaproterenol (indirect PKA stimulator; 
34) and the cell-permeable cAMP analog 8-bromo cAMP (direct PKA 
stimulator) on phosphorylation of p42 MAPK induced by HGF. Both 
metaproterenol- and 8-bromo cAMP-induced potentiation of p42 MAPK 
phosphorylation in the presence of HGF were almost completely blocked by 
AG1478, wortmannin and PD98059. However, they were not blocked by 
rapamycin. In contrast, pretreatment of hepatocytes with the PKA inhibitor 
H-89 (10-7 M; 35) blocked the potentiating effects of metaproterenol or 
8-bromo cAMP on the phosphorylation of p42 MAPK in the presence of HGF. 
Metaproterenol (10-6 M) or 8-bromo cAMP (10-7 M) alone had no significant 
effect on the phosphorylation of p44 MAPK and p42 MAPK (Fig. 4) 
3.5. Activation of p42 MAPK produced by HGF is potentiated by α1-adrenergic 
agonist phenylephrine 
The potentiating effects of α1-adrerenergic agonists on MAPK pathway 
induction by 5 ng/ml HGF were investigated with the α1-adrerenergic agonist 
phenylephrine. HGF in the presence of phenylephrine (10-6 M) caused a more 
rapid and significant increase in p42 MAPK activity than HGF alone. p42 
MAPK activity peaked at 5 min (about 3.5-fold increase from baseline) after 
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addition and rapidly decreased to basal levels within 30 min (Fig. 5A and 5B). 
In contrast, phenylephrine alone did not significantly stimulate p42 MAPK 
activity (data not shown). Phenylephrine (10-6 M) in the presence of HGF did 
not significantly stimulate p44 MAPK phosphorylation (Fig. 5C). The present 
findings indicate that phenylephrine potentiates HGF-induced p42 MAPK 
activity. 
3.6. Effects of specific inhibitors of signal transducers on α1-adrenergic 
agonist- and/or TPA-induced MAPK isoform activity in presence of HGF 
In order to investigate the potentiating mechanism for the α1-adrenergic 
receptor/protein kinase C (PKC) pathway in induction of p42 MAPK activity 
by HGF, we examined the effects of phenylephrine (indirect PKC activator; 7) 
and 12-O-tetradecanoylphorbol-13-acetate, (phorbol ester, TPA; direct PKC 
activator) on the phosphorylation of MAPK isoforms induced by HGF. Both 
phenylephrine (10-6 M)- and TPA (10-7 M)-induced potentiation of p42 MAPK 
phosphorylation in the presence of HGF were almost completely blocked by 
AG1478, wortmannin and PD98059. However, they were not blocked by 
rapamycin. In contrast, pretreatment of hepatocytes with the PKC inhibitor 
sphingosine (10-7 M; 36) blocked the potentiative effects of phenylephrine and 
TPA on the phosphorylation of p42 MAPK induced by HGF. Phenylephrine 
(10-6 M) or TPA (10-7 M) alone had no significant effect on the 
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phosphorylation of p44 MAPK and p42 MAPK (Fig. 6). 
 
4. Discussion  
 The proliferative pathway by which HGF activates the receptor tyrosine 
kinease c-Met/MAPK cascade (ERK pathway) has been described in many 
normal cells and transformed cells (4, 14, 15, 37). The MAPK pathway is one 
of the most important and intensively studied signaling pathways. However, 
there are few studies regarding the HGF-induced activation of MAPK 
isoforms in primary cultured adult rat hepatocytes. Therefore, we 
investigated the possible roles of the MAPK isoforms induced by HGF in 
primary cultures of adult rat hepatocytes. As shown in Figs. 1 and 2, we 
demonstrated that HGF (5 ng/ml) rapidly stimulates p42 MAPK activity, but 
not p44 MAPK activity. p42 MAPK activity was blocked by the MEK 
inhibitor PD98059. Moreover, hepatocyte p42 MAPK activity induction by 
HGF was almost completely blocked by specific inhibitors of signal 
transducers, such as AG1478 and wortmannin, but not rapamycin (Fig.2). 
These results suggest that signal transducers such as receptor tyrosine 
kinase, p42 MAPK and PI3K play an essential role in the mitogenic activity 
induced by HGF under our experimental conditions. The present results are 
consistent with reports that p42 MAPK acts upstream of p70S6K and 
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downstream of receptor tyrosine kinase and PI3K in primary cultures of 
adult rat hepatocytes (15, 39, 40). 
There have been very few studies on the adrenergic agonist-induced 
regulation of MAPK activity. Thus, we examined whether α1- and 
β2-adrenergic agonists modulate the HGF-induced changes in the activity of 
each MAPK isoform. We found that the HGF-induced hepatocyte p42 MAPK 
activity was enhanced by metaproterenol (10-6 M), a β2-adrenergic receptor 
agonist and an indirect adenylate cyclase activator (Fig. 3) (34). In contrast, 
metaproterenol alone had no significant effects on hepatocyte MAPK activity 
in the absence of HGF (Fig. 4). The enhancing effects of metaproterenol in the 
presence of HGF were inhibited by the PKA inhibitor, H-89 (35), thus 
suggesting the involvement of PKA in the effects of metaproterenol (Fig. 4). 
The involvement of PKA in the effects of metaproterenol is supported by our 
previous results indicating that metaproterenol-induced potentiation of 
hepatocyte DNA synthesis and proliferation in the presence of HGF (5 
ng/mL) was completed inhibited by a specific PKA inhibitor, H-89. (10). 
However, the role of the second messenger, cAMP, in the control of 
hepatocyte DNA synthesis and proliferation remains uncertain (39, 40). 
Cyclic AMP can either stimulate or inhibit DNA synthesis depending on 
culture conditions (41-44). For example, elevated hepatocyte cAMP levels 
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have been reported to inhibit HGF-stimulated DNA synthesis and 
proliferation (3). We demonstrated previously that the cell-permeable cAMP 
analog, 8-bromo cAMP also enhanced the p42 MAPK activity and hepatocyte 
proliferation induced by HGF (Fig. 4). These results indicate that the 
β2-adrenergic receptor/cAMP pathway cross-talks with the HGF 
receptor/MAPK pathway to potentiate hepatocyte growth. Because both 
metaproterenol- and 8-bromo cAMP-induced potentiation of p42 MAPK 
activity in the presence of HGF were completely inhibited by AG1478, 
wortmannin and PD98059, but not rapamycin, β2-adrenergic pathway may 
cross-talk with upstream of ERK2. The point(s) of convergence between the 
two signaling cascades may be raf or ras, an upstream element of ERK2 (45). 
A possible scheme for cross-talk between the HGF receptor/MAPK pathway 
and the β2-adrenergic receptor/PKA pathway is shown in Fig.7. The 
discrepancy between other data and our own is unclear at present. Thus, 
more detailed mechanisms of the cross-talk between the HGF-signaling 
pathway and the β2−adrenergic receptor/cAMP/PKA pathway should be 
explored.  
 While phenylephrine alone had no effect on hepatocyte MAPK activity in the 
absence of HGF, HGF-induced hepatocyte p42 MAPK was enhanced by 
phenylephrine, an α1-adrenergic agonist (Fig. 6). The enhancing effects of 
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phenylephrine in the presence of HGF were inhibited by the PKC inhibitor, 
sphingosine (10-6 M; 36), thus suggesting the involvement of PKC in the 
potentiating effects of the α1-adrenoceptor (Fig. 6). The involvement of PKC 
in the effects of phenylephrine is supported by our previous results indicating 
that phenylephrine-induced potentiation of hepatocyte DNA synthesis and 
proliferation in the presence of HGF (5 ng/mL) was completed inhibited by a 
specific PKC inhibitor, sphingosine. (10). However, the roles of the second 
messengers, IP3 and diacylglycerol, in the control of hepatocyte DNA 
synthesis and proliferation remain uncertain (46). Phorbol ester, 
12-O-tetradecanoylphorbol-13-acetate (TPA; 10-7 M), is a direct activator of 
PKC, and can either directly or indirectly stimulate DNA synthesis 
depending on culture conditions (10, 11, 26, 28). In addition, α1-adrenergic 
receptor-mediated signals may interact with upstream signal transducers, 
such as the MEK, raf or ras pathways (47), and have a positive influence 
normal liver growth and liver regeneration in vivo (7, 8, 48, 49). Therefore, 
the potentiating effects of phenylephrine are likely, at least in part, to 
cross-talk with the HGF receptor/MAPK pathway; both phenylephrine- and 
TPA-induced potentiation of p42 MAPK activity induced by HGF were 
completely inhibited by AG1478, wortmannin and PD98059, but not by 
rapamycin. Thus, the α1-adrenergic pathway may interact with upstream 
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elements such as raf or ras (45). A possible scheme for cross-talk between the 
HGF receptor/MAPK pathway and the α1-adrenergic receptor/PKC pathway 
is shown in Fig. 7. More detailed mechanisms of cross-talk between the 
HGF-signaling pathway and the α1-drenergic receptor/PKC pathway remain 
to be explored.  
In conclusion, the present study demonstrates that the cross-talk signals by 
extracellular α1- and β2-adrenoceptor agonists, such as phenylephrine and 
metaproterenol, potentiate HGF-induced p42 MAPK activity in primary 
cultured adult rat hepatocytes. The present findings support the notion that 
endogenous catecholamine-induced potentiation of hepatocyte DNA synthesis 
and proliferation in the presence of HGF play an important role in the 
activation of the MAPK cascade during liver regeneration after partial 
hepatectomy or liver necrosis caused by toxic chemicals in vivo (6,7). There 
are few clear examples of how cells handle or manage various signal 
pathways. Thus, we should also examine whether there is cross-talk between 
catecholamine pathways and those of other growth factors (e.g., epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF), and insulin) in 
primary cultured hepatocytes. 
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Figure legends 
Fig. 1. Time course and patterns of MAPK isoform activity induced by HGF. 
 Isolated hepatocytes cultured for 3 h were washed and incubated in either 
the absence (control; C: medium alone) or presence of 5 ng/ml HGF for the 
indicated times at 37°C. Phosphoyrlated MAPK isoforms (P-p42/P-p44 
MAPK) were identified using anti-phospho MAPK antibody, as described in 
Materials and Methods. Intensity of the Mr 44-kDa and 42-kDa bands 
corresponding to phosphorylated p44 MAPK and p42 MAPK was normalized 
to total MAPK (p42/p44 MAPK (p42/p44 MAPK). A; typical Western blotting 
band, phosphorylated p42 /p44MAPK (P-p42/P-p44 MAPK), total p42/p44 
MAPK (p42/p44 MAPK); B: time-course of phosho-p42 MAPK (ERK2) 
activity; C: time-course of phosho-p44 MAPK (ERK1) activity. Results are 
expressed as a percentage of the respective control value (mean ± SEM of 
three experiments). *P<0.05; **P<0.01 compared with respective controls. 
 
Fig. 2. Effects of specific inhibitors of signal transducers on MAPK isoform 
activity induction by HGF.   
 Hepatocytes were stimulated with HGF (5 ng/ml) in the presence of specific 
inhibitors of signal transducers, such as AG1478 (10-7 M), PD98059 (10-6 M), 
wortmannin (10-7 M) and rapamycin (10 ng/ml). Phosphorylated MAPK 
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isoforms (p44 kDa as ERK 1 and p42 kDa as ERK 2) were determined after 
incubation for 5 min with the test agents. Phosphorylated MAPK isoforms 
were identified using anti-phospho-MAPK antibody as described in Materials 
and Methods. Results are expressed as percentage of the respective control 
value (mean ± SEM of three experiments). **P<0.01 compared with 
respective controls (HGF alone). 
 
Fig. 3. Effects of metaproterenol on time course and patterns of MAPK 
isoform activity induced by HGF. 
 Hepatocytes were stimulated with HGF (5 ng/ml) in the absence or presence 
of metaproterenol (10-6 M). Phosphorylated MAPK isoforms and/or total 
MAPK (A: typical Western blotting band; B: p42 MAPK; and C: p44 MAPK) 
were identified using anti-phospho-MAPK antibody and/or anti-MAPK, as 
described in Materials and Methods. Results are expressed as a percentage of 
the respective control value (mean ± SEM of three experiments). *P<0.05; 
**P<0.01 compared with respective controls. H: HGF; Meta: metaproterenol. 
 
Fig. 4. Effects of specific inhibitors of signal transducers on metaproterenol 
and/or 8-bromo cAMP-induced MAPK isoform activity in the presence of 
HGF.  
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 Hepatocytes were stimulated with HGF (5 ng/ml) plus metaproterenol 
(10-8-10-6 M), and/or 8-bromo cAMP (10-9-10-7 M) in the presence of specific 
signal transducer inhibitors such as AG1478 (10-7 M), PD98059 (10-6 M), 
wortmannin (10-7 M), rapamycin (10 ng/ml) and H-89 (10-7 M). 
Phosphorylated MAPK isoforms (ERK 1 and ERK 2) were determined after 
incubation for 5 min with the test agents. Phosphorylated MAPK isoforms 
(ERK 1 and ERK 2) were identified using anti-phospho-MAPK antibody, as 
described in Materials and Methods. Results are expressed as a percentage of 
the respective control value (mean ± SEM of three experiments). *P<0.05; 
**P<0.01 compared with respective controls (HGF alone). 
 
Fig. 5. Effects of phenylephrine on time course and patterns of MAPK isoform 
activity induced by HGF. 
 Hepatocytes were stimulated with HGF (5 ng/ml) in the absence or presence 
of phenylephrine (10-6 M). Phosphorylated MAPK (A: typical Western blotting 
band; B: p42 MAPK; and C: p44 MAPK) were identified using 
anti-phospho-MAPK antibody and/or anti-MAPK, as described in Materials 
and Methods. Results are expressed as a percentage of the respective control 
value (mean ± SEM of three experiments). *P<0.05; **P<0.01 compared with 
respective controls. H: HGF; Phen: phenylephrine. 
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Fig. 6. Effects of specific inhibitors of signal transducers on phenylephrine 
and/or TPA-induced MAPK isoform activity in the presence of HGF.  
 Hepatocytes were stimulated with HGF (5 ng/ml) plus phenylephrine 
(10-8-10-6 M), and/or TPA (10-9-10-7 M) in the presence of specific inhibitors of 
signal transducers, such as AG1478 (10-7 M), PD98059 (10-6 M), wortmannin 
(10-7 M), rapamycin (10 ng/ml) and sphingosine (10-7 M). Phosphorylated 
MAPK isoforms (ERK 1 and ERK 2) were determined after incubation for 5 
min with test agents. Phosphorylated MAPK isoforms (ERK 1 and ERK 2) 
were identified using anti-phospho-MAPK antibody, as described in Materials 
and Methods. Results are expressed as a percentage of the respective control 
value (mean ± SEM of three experiments). *P<0.05; **P<0.01 compared with 
respective controls (HGF alone). 
 
Fig. 7. Possible model for cross-talk between HGF receptor/MAPK pathway 
and α1- or β2-adrenergic receptor-mediated pathways.  
Abbreviations: HGF, hepatocyte growth factor; TK, receptor tyrosine kinase; 
AC, adenylate cyclase; PLC, phospholipase C; PI3K, phosphatidylinositol 
3-kinase; MEK, MAP kinase kinase; MAPK, mitogen-activated protein 
kinase; p70S6K, p70 ribosomal protein S6 kinase; PKA, protein kinase A; 
PKC, protein kinase C; DG, diacylglycerol; IP3, inositol 1, 4, 5-triphosphate. 
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